We are committed to developing breakthrough precision medicines for common diseases with large unmet medical needs.
Over the past 20 years, significant advances in human genetics and in the understanding of the biological processes underpinning disease have opened the door to a multitude of new potential therapeutic targets, which we believe presents a unique opportunity for a new approach to precision medicine. Based on insights from our Compass platform, which leverages variant functionalizaton, we design precision medicines that take into account the genetic drivers of disease.
Our commitment to Kidney Disease
Maze Therapeutics is developing medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants and help halt the progression and potentially reverse the effects of kidney disease. Our most advanced lead program is directed against APOL1-mediated kidney disease (AMKD). Learn more about our pipeline focused on targeted treatements for chronic kidney disease here.
